

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Rasagiline Mesylate Tablets (1mg) from National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug and regarded as passing the consistency evaluation.

As stated in the Company’s announcement dated 26 January 2024, the Group’s Rasagiline mesylate has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market. Rasagiline Mesylate Tablets is mainly used for patients with primary Parkinson’s disease as a monotherapy, and in combination with Levodopa for such patients with end-of-dose fluctuations as a combination therapy.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 21 May 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.